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 Our deepest fear is not that we are inadequate. Our deepest fear is that we are 
powerful beyond measure. It is our light, not our darkness, that most frightens us. You 
playing small does not serve the world. There is nothing enlightening about shrinking 
so that other people won’t feel insecure around you. We are all meant to shine as 
children do. It’s not just in some of us; it is in everyone. And as we let our own lights 
shine, we unconsciously give other people permission to do the same. As we are 
liberated from our own fear, our presence automatically liberates others.  
 
- Marianne Williamson 
 
  
 ABSTRACT 
 
The studies in this thesis examined several key determinants for successful uptake of 
vaccinations in the Nordic countries, with focus on vaccine safety and vaccine 
effectiveness. 
 
In study I, we investigated whether disease history is a risk factor for narcolepsy after 
vaccination with the pandemic influenza vaccine, Pandemrix, which was circulated 
between 2009 and 2010. The results showed that there was no association between 
disease history and narcolepsy. We also found evidence for confounding by 
indication, with a larger number of prescriptions/diagnoses for nervous system 
disorders and mental and behavioural disorders when we did not adjust for the timing 
of vaccination or vaccination status. This could suggest that early cases of narcolepsy 
were initially misdiagnosed prior to narcolepsy diagnosis.  
 
In study II, we investigated the effect of the quadrivalent humanpapillomavirus 
(qHPV) vaccine on genital condyloma by the number of doses and time between 
doses. This cohort study followed young Swedish girls ages 10-27 for HPV 
vaccination and condyloma. The results showed that the greatest protection against 
condyloma was seen after two doses of qHPV vaccine with 4-7 months between dose 
one and two. We also found that girls, who initiated vaccination at a younger age, had 
a greater protection against condyloma.  
 
The results from these studies show just how complex the improvement of 
vaccination programmes can be. On one hand, we see the difficulties in assessing 
what went wrong following the introduction of a vaccine into a population– it is not 
always possible to predict a rare outcome from a mass vaccination campaign, so 
vaccine safety becomes a paramount concern from a societal perspective. We also see 
what happens when a vaccine proves its effectiveness in a population-based setting to 
the point where the number of doses can be reduced without compromising its 
effectiveness. Improving the vaccination programmes is, therefore, a complex 
multifactorial problem with many key determinants that can change depending on the 
vaccine in question e.g. mass vaccination versus routine vaccination.   
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1. INTRODUCTION 
 
Although the relative time that vaccinations have been available is short, the impact 
they have had is hard to exaggerate [1]. The success of vaccination on reducing 
mortality would lead to the forming of national vaccination programmes still in use 
today. For some vaccines, when the coverage in the population is high enough the 
disease can be eradicated altogether. Smallpox, for example, was a good contender for 
eradication as symptoms were evident and recognisable, the lag time between 
exposure and disease was short (limiting transmission of disease in the population), 
the vaccination provided life-long immunity to disease and only humans were 
affected i.e. there was no animal reservoir [2]. However, for diseases that utilise 
animal reservoirs e.g. tick-borne encephalitis (TBE), eradication can be a far more 
complicated process. Even if everyone in the world was vaccinated simultaneously, 
the virus would still be circulating in infected animals, and should immunity falter in 
humans, the disease would likely re-emerge in the population. This is further 
complicated in vaccines with low efficacy (like TBE) as immunity wanes over time 
and this can result in re-emergence of disease. Further, not all vaccines offer life-long 
protection against disease with immunity waning over time e.g. pertussis and 
diphtheria or the strain in circulation continuously changing e.g. influenza [1]. These 
factors, therefore, make eradication of some diseases nearly impossible and the only 
option is to prevent and control the diseases in the population and focus on reducing 
the mortality and complications associated with those diseases.  
 
1.1 HERD IMMUNITY 
 
Disease prevention and control in a population requires enough individuals having 
immunity to a particular disease. This concept is known as herd immunity. Herd 
immunity can be achieved through 1) natural immunity, whereby the individual has 
had the disease and recovered: 2) acquired immunity, which is when the person has 
been vaccinated and is no longer at risk of contracting the disease. Herd immunity is 
best achieved through the use of immunisation programmes, which work by inducing 
long-term protection without the risk to the individual of acquiring the natural disease.  
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There is also an indirect effect of vaccinations or ‘herd protective’ effect, whereby the 
transmission of infection (person-to-person) within a population is hindered (as the 
number of individuals becomes immune from infection) and an increase in herd 
immunity could see a decreased risk of an uninfected person becoming infected. This 
can also be thought of as protection for persons who are unvaccinated in the 
population [3-6].  
 
1.2 POTENTIAL STAGES IN THE EVOLUTION OF A 
VACCINATION PROGRAMME 
 
 
Figure 1. Diagram adapted from Chen RT et al. Vaccine Adverse Event Reporting System 
(VAERS). A passive surveillance system in the US intended to collect reports of reactions to 
vaccines. Under the aegis of the US Centers for Disease Control and Prevention and the US 
Food and Drug Administration. (VAERS). Vaccine, 1994: 12(6):542–550. 
 
In Figure 1, we see potential stages in the evolution of an immunisation programme. 
In Stage1 (pre-vaccine), there is a high incidence of mortality and morbidity from 
infectious disease. In stage two, a vaccine is introduced, and as the coverage of the 
vaccine increases, the incidence of disease in the population decreases. In stage three, 
the benefits of the vaccine are most apparent and vaccine coverage is high: however, 
vaccine safety concerns increase in the population as the number of adverse events 
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increases with the higher number of vaccinated individuals. This results in a loss of 
confidence in the vaccine, a reduction in vaccine coverage and resurgence of the 
disease in the population. In stage four, the resurgence of disease (outbreaks) or 
availability of an alternative vaccine, for example, results in renewed public 
acceptance of vaccination. The coverage of vaccine increases once more and the 
incidence of disease in the population decreases. In stage five, vaccine-preventable 
diseases like smallpox that can be eradicated, vaccine use can be stopped, thereby 
removing the risk of adverse events. The aim of vaccination programmes today is to 
maintain high coverage of vaccines so that we remain in stage four and with certain 
diseases such as measles strive for eradication. This is only possible if enough people 
are vaccinated in the population and immune from disease (herd immunity).  
 
Unfortunately, despite the obvious benefit of vaccination programmes, vaccines have 
become victims of their own success with an increasing number of people opting out 
of vaccination. Part of the problem is that before vaccinations were introduced, 
vaccine-preventable diseases were sufficiently common in the population that risks 
associated with the diseases were abundantly obvious. Conversely, in today’s society, 
an increasing number of healthcare workers (HCWs) and the general public have 
never seen the diseases in real life and therefore base the decision to vaccinate on 
what they do know; which is often more focused on the side effects and pain 
associated with the vaccination itself. This has resulted in some scepticism regarding 
the importance of continued vaccination, particularly with an increasing number of 
new vaccines offered to children as part of a routine vaccination schedule [7, 8]. In 
addition, there is often a lack of knowledge regarding the risks and benefits of 
vaccination, which can lead to a significant number of parents having doubts about 
vaccination [7, 9-12]. A key determinant of whether a parent chooses to get their child 
vaccinated is HCWs, as they are considered a primary and trustworthy source of 
information into the benefit of vaccination and therefore their knowledge about 
vaccines are important in maintaining public confidence [7, 13-18]. 
 
Although the uptake of vaccinations is high in the Nordic countries, it is not 
uniformly so. Population-wide compliance for vaccination programmes is an 
extremely difficult task, but ensuring public acceptance and trust in vaccinations e.g. 
through good communication, transparency of information and trust in the healthcare 
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system and healthcare workers can go a long way to help ensure the uptake of 
vaccines remains high. The purpose of this thesis is to explore key factors like vaccine 
safety and effectiveness on vaccine uptake.  
 
1.3 VACCINE EFFICACY AND EFFECTIVENESS 
 
Vaccine efficacy is a measure of the difference in disease risk between vaccinated and 
unvaccinated individuals under ideal conditions. Randomised control trials (RCTs) 
are used to ascertain efficacy outcomes, whereby optimal conditions are maintained 
throughout the trial period. This means that the efficacy outcomes are not directly 
generalisable to the general population. 
 
Vaccine effectiveness (VE) is a term used to reflect outcomes in a non-controlled 
environment and from a public health perspective, collecting data on vaccination 
individuals in the population is preferable to RCTs, as outcomes are more reflective 
of what is happening in the population where the environment is not controlled [19]. 
The Swedish healthcare registers provide the means for us to assess effectiveness in 
real-life settings and factor in access, distribution and detect changes in herd 
immunity [19, 20]. 
 
1.4 VACCINE SAFETY 
 
The introduction of new vaccines (or medicines) follows extensive safety monitoring 
and for most vaccines included in the national programmes, there is data on the 
longer-term safety of these vaccines in the population. However, for annual vaccines 
like influenza – that alter each year depending on the circulating strains, longer-term 
information on their safety in a population is generally not available [21]. In these 
instances, very rare outcomes from the vaccination will only be discovered from post-
vaccination surveillance in a larger population [21, 22]. A challenge with adverse 
events following vaccination (particularly for those that are rare) is identifying 
whether it was the vaccine itself that caused the outcome or just something that 
randomly occurred in that population [23].  
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2. BACKGROUND 
 
2.1 STUDY I INVESTIGATING THE SIDE EFFECTS OF 
PANDEMIC INFLUENZA VACCINATION  
 
Study I is a vaccine safety study looking at whether disease history is a risk factor for 
narcolepsy after vaccination with the pandemic influenza vaccination, Pandemrix, 
administered between 2009 and 2010. 
2.1.1 Mass vaccination campaigns 
 
During mass vaccination campaigns, large numbers of people are vaccinated over a 
relatively short period of time against a particular disease. The most widely accepted 
reason for doing this is to prevent an outbreak occurring in the population by rapidly 
increasing herd immunity and reducing the risk of complications from disease [24].  
Examples of mass vaccination include meningococcal disease [25], Japanese 
Encephalitis [26], yellow fever [27] and influenza. 
 
In June of 2009, in response to the global A(H1N1) influenza pandemic, four vaccines 
were manufactured for use in the European Union (EU), with three being authorised 
for use through the central European Medicines Agency (EMA) in the EU member 
states [22]. Influenza viruses are prone to antigenic shift and can cause pandemics 
with little warning, which can lead to a limited number of available doses of vaccine 
worldwide. Due to the severity of avian influenza strains specifically, the World 
Health Organization (WHO) encouraged the inclusion of adjuvants when the vaccines 
were being developed, as they have been shown to reduce the amount of antigen 
needed to provide a longer lasting protection against influenza [22]. Adjuvant AS03, 
in particular, has been shown to stimulate increased local or systemic reactions within 
three days of initial vaccination compared to vaccines that do not contain adjuvants; 
up to 2009 no major reactions were reported [22, 28, 29]. Due to the speed of the 
transmission of swine flu and there only being a small quantity of A(H1N1) 
vaccinations available, the immunisation strategy mimicked the annual influenza 
campaigns with the vulnerable being offered the vaccination first [22, 30]. In 2009-
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2010 millions of individuals were vaccinated in Europe with one of the three H1N1 
pandemic vaccines (Celvalpan, Focetrai and Pandemrix). According to estimates 
provided by the EMA by the 8th August 2010, at least 38.6 million individuals in 
EU/EEA countries had been vaccinated with one of the pandemic vaccines -
Pandemrix being the most commonly used with <30.5 million individuals vaccinated 
[21, 31].  
2.1.2 Adverse events following the pandemic influenza 
vaccination 
 
In August 2010, the Swedish Medical Product Agency (MPA) and the Finnish 
National Institute reported abnormally large numbers of narcolepsy cases following 
vaccination with A(H1N1)pdm09 vaccination. In both Sweden and Finland, 
Pandemrix was the only pandemic influenza vaccine used, and in Sweden, 60% of the 
population had been vaccinated [32]. Similar associations between Pandemrix and 
narcolepsy were reported through studies conducted in other countries [33-36]. The 
European Centre for Disease Prevention and Control (ECDC) requested that the 
Vaccine Adverse Event Surveillance and Communication (VAESCO) consortium 
carry out a formal investigation. Several Nordic countries also carried out their own 
rapid assessment studies, particularly focussed on children and adolescents [32, 35, 
37-40]. Several studies have investigated potential risk factors for the development of 
narcolepsy in conjunction with the pandemic vaccine, with some speculating that 
narcolepsy might be an autoimmune disease [41, 42], wild A(H1N1) pandemic 
influenza infection itself may play a role in narcolepsy development [43-46] or 
streptococcal infection is a trigger [43, 47], but as yet the actual trigger remains 
unknown [23]. 
 
2.1.3 Narcolepsy 
 
 
Narcolepsy is one of the major sleep disorders characterised by excessive daytime 
sleepiness (EDS) and cataplexy [35]. There are two main types of narcolepsy, Type 1 
(narcolepsy with cataplexy) and Type 2 (narcolepsy without cataplexy), these types 
were more clearly defined in 2017 based on research findings that had been carried 
out over the last five years. Narcolepsy has a strong association with the HLA-
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DQB1*06:02 allele and that it is specifically the loss of hypothalamic hypocretin 
(orexin)-producing neurons that lead to the development of the disease [42, 48, 49].  
 
2.1.4 Narcolepsy diagnosis 
 
 
Narcolepsy is a chronic hypersomnia syndrome with an estimated incidence of 1 per 
100,000 individuals annually [50]. It can take 10-15 years from first symptoms until 
diagnosis, with a peak of onset occurring during the second decade [50-53]. In 
addition, as its symptoms are similar to other illnesses e.g. depression, ADHD, sleep 
disorders and infections, this can contribute to the delay in diagnosis. There are seven 
diagnostic sleep centres and/or neurophysiology labs in Sweden, responsible for the 
investigating suspected sleep-related disorders, such as narcolepsy, as well as other 
nervous/neurological disorders. The centres receive referrals from General 
Practitioners (GPs) and specialists from healthcare centres all over Sweden when a 
disease such as narcolepsy is suspected. There are various tests that can be performed 
including; a Polysomnogram, a Multiple Sleep Latency Test (MSLT) and a 
hypocretin test.  
 
 In a polysomnogram, the patient remains at the centre overnight and their 
brain activity is monitored along with heart rate, eye movements and blood 
pressure. This test determines typically how long it takes for the patient to fall 
sleep, whether rapid eye movement (REM) sleep occurs once a sleep, and how 
often the patient wakes during the night.  
 An MSLT is carried out during the daytime and is a test for excessive daytime 
sleepiness. Brain activity is measured throughout, which basically measures 
how quickly the patient falls asleep, in a quiet location, during the daytime. It 
also determines whether REM sleep is achieved after falling sleep.   
 A hypocretin test can also be used to measure the amount of hypocretin there 
is in the cerebrospinal fluid through performing a spinal tap.  If a patient has 
narcolepsy, the level of hypocretin will be low.  
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2.2 STUDY II INVESTIGATING WHETHER A TWO-DOSE 
SCHEDULE IS AS EFFECTIVE AS A THREE-DOSE SCHEDULE 
AGAINST CONDYLOMA 
 
 
Study II is a VE study looking at whether two doses of quadrivalent human 
papillomavirus (qHPV) vaccination is as effective as three doses, provided there is an 
optimal time between administration of dose one and two.  
 
Papillomaviruses are an extensive family of viruses that can be found in most 
mammals and birds. Human papillomaviruses (HPV) are spread through skin-to-skin 
contact, typically during sexual activity and the risk of becoming infected with HPV 
is particularly high when the partner has had a large of sexual partners [54] and while 
most infections are asymptomatic, 75-80% of most women will have had an HPV 
infection at some point during their life. Infection with HPV is typically self-limiting, 
and 90% of cases will clear the infection within two years from initial infection [55]. 
To date, over 200 types of HPV have been identified [56, 57], roughly 40 of which 
can be transmitted sexually. According to the International Agency for Research on 
Cancer (IARC), there are 13 high-risk oncogenic HPV types [58] with types 16 and 
18, which cause 70% of cervical cancer cases globally, being of specific interest in 
vaccine development [59]. Low-risk HPV types 6 and 11 are responsible for about 
90% of condyloma cases [60].  
 
Globally, cervical cancer is the fourth most common cancer to affect women during 
childbearing years [61]. In 2012, there were 528 000 new cases of cervical cancer 
diagnosed around the world, with 266 000 women succumbing to the disease, with 
90% of deaths from cervical cancer occurring in less developed countries [62]. For 
countries with improving social and economic status e.g. Western Europe, Americas 
etc. the last 30 years have seen a noticeable reduction in cervical cancer incidence and 
mortality, coinciding with the successful implementation of secondary prevention 
efforts, notably screening and the subsequent early identification of cancer or pre-
cancerous malignancies, diagnosis and treatment of cervical cancer [62].  
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2.2.1 Prophylatic HPV vaccines 
 
HPV vaccines are subunit L1 virus-like particles (VLPs) vaccines and contain an 
adjuvant. An antibody response is triggered as a result of self-assembly of the L1 
capsid protein into VLPs. There are three vaccines currently available: 
 
 A bivalent HPV (bHPV) vaccine (CervarixTM; GlaxoSmithKline) was 
approved by the EMA in 2007 and two years later by the FDA [63, 64]. The 
bHPV vaccine provides protection against high-risk HPV types 16 and 18.  
 The qHPV vaccine (GardasilTM; Merck), received marketing authorisation 
from the EMA and the Food and Drug Administration (FDA) in 2006 [65, 66]. 
The qHPV vaccine offers protection against high-risk HPV type 16 and 18 and 
low-risk HPV types 6 and 11. Gardasil has shown to have upwards of 99% 
efficacy against HPV 16 and 18 in HPV-negative women [67]. 
 A 9-valent HPV (pvHPV) vaccine (Gardasil 9TM; Merck) was approved by 
EMA and FDA in 2014 and 2015 respectively [68, 69]. This vaccine 
additionally provides protection against high-risk HPV types 31, 33, 45, 52 
and 58 that are believed to cause roughly 20% of cervical cancers.  
 
2.2.2 qHPV vaccination in Sweden 
 
In 2007, an opportunistic qHPV vaccine was available at a subsidised price for girls 
aged 13-17 in Sweden, vaccines given to girls outside of this age range were paid for 
by the recipient. In 2012, qHPV vaccination became part of a routine school-based 
vaccination programme aimed at girls aged between 10 and 12, with a catch-up 
vaccination for girls aged between 13 and 18 years. Recommendations for the qHPV 
vaccine were for it to be administered as part of a 3-dose schedule given at 0, 2 and 6 
months. In December 2014, the one-dose vaccination coverage for qHPV in the 
childhood vaccination programme was 82% and for subsidised and catch up 
vaccination nearly 60% [70, 71].  
 
2.2.3 qHPV vaccine effectiveness 
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Nationwide VE studies are necessary to determine the public health impact of the 
qHPV vaccine on HPV-related outcomes in that country. Following the introduction 
of the qHPV vaccine, it was evident that the vaccine was not only effective in a 
population-based setting on condyloma and cervical abnormalities [72-76] but that 
there was a possible non-inferiority of two-doses compared to three-doses for young 
women [77]. In 2014, in accordance to the existing information, the EMA and World 
Health Organization Strategic Advisory Group of Experts (SAGE) recommended a 
two-dose HPV vaccination schedule for girls younger than 14 years of age, with 0-6 
months between first and second dose of qHPV [78] and in January 2015, Sweden 
introduced a two-dose HPV vaccination programme for young girls [78, 79].
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3. AIMS 
 
 
Paper I: To investigate disease history before A(H1N1)pdm09 vaccination as a risk 
factor for narcolepsy. 
 
Paper II: To assess incidence of condyloma after two doses of qHPV vaccine, by 
time since first dose, in girls and women initiating vaccination before age 20. 
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4. MATERIAL AND METHODS 
 
 
4.1 DATA SOURCES AND COLLECTION 
 
The studies in this thesis were granted ethical approval by the Regional Ethical 
Review Board in Stockholm. This chapter aims to provide information about data 
sources, exposures, outcomes and designs of the studies.   
 
A personal identity number (PIN) is allocated to all individuals that are resident in 
Sweden, for at least one year [80]. Individual-level data can be obtained from the 
Swedish national health data registers and linked to other registers using the PIN. The 
responsibility for data linkages falls to the National Board of Health and Welfare and 
Statistics Sweden, who on completion replace the PIN by a de-identified study ID that 
cannot be traced back to the individual [80]. 
 
4.1.1 Swedish healthcare registers 
 
Total Population Register, Migration Register, and Multigeneration Register 
 
The Total Population Register (TPR) was established in 1968 and is held at Statistics 
Sweden. The TPR is a main source for demographic data that can be linked to other 
registers using in individuals PIN number [81]. The migration register was established 
in 1968 and contains information regarding immigration and emigration dates. The 
multigeneration register (MGR) was created in 1991 when the responsibility for 
registering addresses was taken over by the Swedish Tax authorities. This register 
contains a list of familial relations, including information on adoptive or biological 
parents. Both the Migration register and the MGR are both extracted from the TPR 
[82]. 
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The National Patient Register (NPR) 
 
In the 1960s the National Board of Health and Welfare established the NPR, at this 
time it only held information on region-specific inpatient coverage. The NPR gained 
national coverage in 1987 and in 1997 outpatient (day surgery) data was additionally 
added to the NPR. Outpatient data became systematically added to the NPR in 
2001[81]. The International Classification of Diseases (ICD) with the 10th revision of 
ICD in use since 1997 [83] is used to report diagnoses to the NPR.  
 
The National Causes of Death Register (CDR) 
 
The CDR established by Statistics Sweden contains information on all deceased 
individuals residing in Sweden from 1952 onwards. It contains the date of death, the 
cause of death and information on deaths that occur abroad. In 1994, it was moved to 
the National Board of Health and Welfare [84]. 
 
The Prescribed Drug Register (PDR) 
 
In July 2005, information on pharmacy-dispensed drug prescriptions became part of a 
newly automated register called the PDR. The PDR is held at the National Board of 
Health and Welfare and has had national coverage from the beginning. Drug and 
vaccine prescriptions are entered into the register using Anatomical Therapeutic 
Chemical (ATC) codes [85].  This register lacks information about school-based 
vaccinations and hospital administrated medications and prescriptions.  
 
Swedish HPV Vaccination register (SVEVAC)  
 
SVEVAC was originally created in 2002 for use in three counties as a voluntary 
system to register childhood vaccinations. In 2006, coinciding with the launch of the 
HPV vaccination in Sweden, SVEVAC was given nationwide coverage for 
registration of HPV vaccination specifically. In 2015 the responsibility of the register 
moved to the Swedish Association of Local Authorities and Regions (SKL).  
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Informed consent is needed from the parent or vaccinated individual. If informed 
consent is lacking, then the person is added anonymously (lacks a PIN), this means 
that any information obtained from SVEVAC cannot be linked to other registers. This 
means that it is not possible to identify whether the information is from one or more 
persons and, for example, whether someone receives one dose of the qHPV vaccine or 
multiple doses. In 2012, there was a change to the informed consent form on a 
municipality level (opt-out to opt-in), this led to a spike in anonymous registrations in 
a few counties in Sweden. It was later changed back to an opt-out information consent 
form.  
 
4.2 STUDY DESIGN 
 
4.3 STUDY I  
 
A retrospective case-control design was used for study I, where cases of narcolepsy 
(outcome) were compared to controls without narcolepsy, to identify whether disease 
history was a risk factor for narcolepsy after A(H1N1)pdm09 vaccination.  
 
4.3.1 Case and control identification 
 
Six of the seven sleep centres in Sweden provided a list of potential cases (those 
referred for an MSLT between January 1st, 2009 and December 31st, 2010). There 
were 431 people who were referred for a possible sleep-related disorder, with 142 
having a primary diagnosis by their referring clinician. These cases were contacted by 
Karolinska Institutet (KI) requesting permission to include them in the study. A case’s 
referral date for an MSLT was defined as the index date in this study.  
 
For each case four controls were randomly selected from TPR, matching on age, 
gender, county of resistance and index date.  
 
Case and control identification and reasons for not fulfilling inclusion criteria can be 
seen in Figure 2.  
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7 national diagnostic sleep 
centres/neurophysiology labs* 
  
Confirmed cases of narcolepsy by 
referring clinician or clinic n= 142 
Potential cases referred for MSLT in 
study period n=431 
Cases excluded: non-participation 
(n=27), no contact (n=18) 
Valid cases that provided consent n= 72 
Controls selected from 
population register 
n=1620 
Control exclusions: did not 
respond to invitation (n=1057), 
refused (n=152), not matched to 
cases included in study (n=156), 
dropped out (n=4) 
Cases with matched controls included in the study 
n=323 
Invalid cases, due to MSLT for 
other reasons than narcolepsy 
n= 289 
Source population N=9.4 million 
Controls that provided 
consent 
n=251 
Figure 2. Flowchart to show case and control identification * No response from one sleep centre, list of potential cases not provided. 
Cases excluded: No Brighton 
Classification Criteria (n=8), 
referral outside study period 
(n=7) 
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4.3.2 A(H1N1)pdm09 vaccination 
 
Information on A(H1N1)pdm09 vaccination was collected via telephone interview 
with cases and controls.  Some dates were missing information e.g. day or month – as 
individuals were unable to recall the exact date of vaccination. In these instances, the 
day of the month was assigned to the 15th (middle of a standard month) with missing 
months in 2009 given November and in 2010 given January. These months represent 
the middle of October-December and middle of overall vaccination period of October 
2009-March 2010 respectively.  
 
4.3.3 Exposures 
 
Disease history  
 
Table 2. Information on disease history selected from the PDR and the NPR  
 
Code Disease Source 
ICD10   
G00-473, G475-99 Nervous system disorders NPR 
F00-99 Mental and behavioural 
disorders 
NPR 
A30-49 Bacterial diseases NPR 
C00-99 Neoplasms NPR 
J00-99 Respiratory diseases NPR 
A80-99 Viral infections of the CNS NPR 
B25-34 Other infections of the CNS NPR 
B95-99 Other bacterial, viral and 
other infectious agents 
NPR 
E10-14 Diabetes Mellitus NPR 
ATC*   
N Nervous system disorders PDR 
R03 Obstructive airway diseases PDR 
J01 Antibacterial PDR 
J05 Antiviral PDR 
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M01A Anti-inflammatory/anti-
rheumatic drugs, non-steroid 
PDR 
L04 Immunosuppressant PDR 
A10 Diabetes PDR 
N06BA01, N06BA03, 
N06BA04, N06BA07 and 
N06BA09 
ADHD treatment and no 
tropics (proxy for ADHD 
diagnosis) 
PDR 
*Drugs used against listed diseases 
 
Four combined exposure groups were also created a) nervous system disorders using 
ATC code N and/or ICD10 codes G00-473, 475-99 b) bacterial diseases using ATC 
code J01 and/or ICD10 A30-49 c) respiratory diseases using ATC code R03 and/or 
ICD10 J00-99 and d) viral diseases using ATC code J05 and/or ICD10 A80-99, B24. 
A multiple prescription/diagnosis variable was also created, taking into account that 
individuals could have received more than one prescription and/or diagnosis during 
the period of exposure in more of more categories.  
 
Exposure windows 
 
Disease history was studied as a risk factor for narcolepsy over three different 
exposure windows (Figure 3).  
 
 
 
Figure 3. Exposure window: 1) Prescription (ATC) and diagnosis (ICD10) history before the 
index date (MSLT-referral date). Defined as after the first date in inpatient register (1987), 
outpatient register (2001) or PDR (2005) up until index date; 2) Prescription and diagnosis 
history during the vaccination period, defined as six month before to one month after 
vaccination date (specific to each case/control). For acute infections ATC J01 and J05, 
vaccination period was two weeks before to two weeks after vaccination; 3) Prescription and 
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diagnosis history before A(H1N1)pdm09 vaccination. Defined as after the first date in 
inpatient register (1987), outpatient register (2001) or PDR (2005) up until vaccination date.  
 
4.4 STUDY II 
 
A register-based cohort study design was used for study II. The effect of vaccination 
within the population was assessed among women aged 10-27 years who had received 
at least two doses of qHPV during the study period. These women were followed for 
HPV vaccination (exposure) and condyloma (outcome). All women who were 
diagnosed with condyloma before the study period were excluded.   
 
4.4.1 Study population 
 
In this study, we included women aged 10-27 years that lived in Sweden between 1st 
January 2006 and 31st December 2012. Girls entered the study cohort on the date of 
administration of the second dose of qHPV. They were followed for the first 
occurrence of condyloma. Women that had a history of condyloma i.e. had received a 
diagnosis prior to follow-up, were excluded, as were girls who emigrated, received 
the bivalent vaccine, initiated qHPV vaccination over the age of 20 or turned 27 
before the start of follow up. Women were followed from their 10th birthday or start 
of follow-up until they were diagnosed with condyloma or one of the censoring 
criteria was met, i.e. death, emigration, bHPV, turned 27 or end of study period.  
 
Details on study exclusions and the population that was analysed in this study can be 
seen in Figure 4. 
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Figure 4. Details on study exclusions and the population analysed to investigate timing of 
two versus three doses of qHPV vaccine and associated effectiveness against condyloma.  
 
4.4.2. Exposure 
 
 
Between the years 2007 and 2011 (opportunistic vaccination period) vaccination were 
registered in SVEVAC. However, reimbursement for the vaccination was only 
possible if the vaccine doses were administered from a pharmacy during this period, 
and thus information regarding vaccinations could also be found in the PDR.  School-
based vaccinations (from 2012) are all registered in SVEVAC and from 2013 in 
National Vaccination Register (NVR). As there were incomplete vaccination records 
for doses one and two in SVEVAC during the course of the study, information was 
complemented with prescription data collected from the PDR, using ATC codes 
J07BM01 and J07BM02 respectively. Dispensation dates that occurred more than 14 
days prior to or directly after the vaccination administration date were considered new 
doses [86]. 
 
336 259 girls and women vaccinated with two doses 
of qHPV, aged 10-27 years living in Sweden 
between January 2006 to December 2012 were 
included in the source population 
 
71 761 excluded 
60077 enter after the study period 
7920 were >19 years of age before start of follow-up 
2133 had a condyloma diagnosis before start of follow-up  
1098 reached 27 before start of follow-up 
480 had emigrated before start of follow-up 
53 were vaccinated with bivalent vaccination before start of follow-up 
264 498 girls and women included in study cohort 
 79 042 received two doses 
 185 456 received three doses 
 
 
 
20 
 
4.4.3 Outcome 
 
Condyloma cases were identified from the NPR using a unique identifying ICD10 
code (A63.0). In addition, cases were identified from the PDR using ATC codes 
D06BB04 and D06BB10 (condyloma treatment podophyllotoxin and imiquimod 
respectively). While podophyllotoxin is used solely for the treatment of condyloma 
imiquimod can also be used to treat other conditions e.g. actinic keratosis. One 
episode of condyloma can have multiple entries in both the NPR and PDR and 
therefore subsequent cases of condyloma cannot be reliably identified 
 
4.5 STATISTICAL ANALYSIS 
 
4.5.1 Study I 
 
 
In order to investigate whether disease history was a risk factor for narcolepsy, 
conditional logistic regression was used to estimate odds ratios (OR) and 95% 
confidence intervals (CI). As narcolepsy is a rare disease, the ORs were interpreted as 
the relative risk (RR) of narcolepsy. 
 
In this study, three analyses were performed investigating disease history as a risk 
factor for narcolepsy: 
 
1. A full data analysis, where all cases and controls were included, regardless of 
vaccination status (vaccinated or not) or timing of vaccination (before or after 
MSLT-referral date). In this analysis, we looked at disease history before the 
index date (exposure window 1, Figure 3).  
2. Second, a vaccinated-only analysis was conducted where only cases/controls 
that received the vaccination before their index date were included - all 
exposure windows were of interest (Figure 3).  
3. Third, a case-only analysis was carried out, which compared those vaccinated 
with an index date before vaccination, versus those with an index date after 
vaccination. The exposure windows of interest were 2 and 3 (Figure 3). 
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4.5.2 Study II 
 
The incidence of condyloma was reported as crude incidence rates (IRs) per 100 000 
person-years with 95% confidence intervals (CIs). These crude IRs were stratified by 
time between the first and second dose of qHPV (0-3, 4-7 or 8+ months) and 
calculated for two separate age-at-first vaccination categories (10-16 years and 17-19 
years), reflecting median age for sexual debut in Sweden [87]. 
 
Poisson regression analysis was used to model IRs in relation to the time between the 
first and second dose of qHPV and age at first vaccination, adjusted for attained age. 
For individual follow-up, the underlying timescale was attained age, split into five 
categories (10-13, 14-16, 17-19, 20-21 and 22+ years) to reflect the risk of 
disease/infection with advancing age. Three versus two doses of qHPV was treated as 
a time-varying exposure, meaning that women could contribute person time to both 
dose groups. Incident rate ratios (IRRs) with 95% CIs were calculated from this 
model after two doses of qHPV relative to three different reference groups (all 
initiating vaccination at the same age): 
 
1) Women who received three doses of qHPV according to the standard dosing 
schedule (0, 2, 6 months).  
2) Women with three doses of qHPV with the same timing between first and 
second dose (two doses with 0-3 months between versus three doses with 0-3 
months etc.).  
3) Women who had received all three of the qHPV doses, with no restriction on 
the time between doses e.g. one to two and two to three.   
 
IRs and IR differences (IRDs) and 95% CIs were predicted from the models 
(averaged across levels of attained age).  
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5. MAIN FINDINGS AND DISCUSSION 
 
 
5.1 STUDY I 
 
 
In study I disease history as a risk factor for narcolepsy after A(H1N1)pdm09 
vaccination was estimated using conditional logistic regression. In total 72 cases and 
251 controls were included in the study (range 3-69 years, mean 19 years).  
 
In the full data analysis, including all cases and controls regardless of vaccination 
status or timing of vaccination (before or after MSLT referral), the risk of narcolepsy 
was increased in individuals with a disease history (prescription and/or diagnosis) of 
nervous system disorders (OR range 3.6-8.8), ADHD (OR=4.5 95% CI 1.4-14.7) and 
mental and behavioural disorders (and OR=3.8, 95% CI 1.6-8.8) before MSLT 
referral (See Table 6). It was speculated whether the increased risk we observed for 
ADHD could have been due to misdiagnosis, which would have also increased the 
risk we observed for nervous system disorders and mental and behavioural disorders.  
 
Table 6. Full case-analysis showing association between disease history before index 
date on the risk of developing narcolepsy. 
 Full-case analysis* 
Characteristics 
  
Cases N (%) Controls  
N (%) 
OR (95% CI)  P-
value 
ICD10*     
 G00-473, 475-99 10 (13.89) 6 (2.40) 8.76 (2.68-28.61) 0.0003 
F00-99 13 (18.06) 14 (5.58) 3.76 (1.60-8.81) 0.002 
Multiple ICD10 31 (43.06) 71 (28.29) 2.39 (1.30-4.39) 0.005 
ATC*      
N 21 (29.17) 30 (11.95) 3.55 (1.77-7.13) 0.0004 
N06BA 7 (9.72) 5 (1.99) 4.49 (1.37-14.71) 0.01 
R03 13 (18.05) 31 (12.35) 2.14 (1.00-4.57) 0.049 
Multiple ATC 57 (79.17) 142 (56.57) 3.30 (1.72-6.33) 0.0003 
*before MSLT referral. N.B Table 4 only shows significant results. Full table of results can be found in 
paper 1 at the back of the thesis.  
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It was possible to look at the case diagnoses ‘overall’ i.e. determine whether they 
were more likely to have received a diagnosis for other sleep-related disorders, which 
would support the hypothesis that early narcolepsy cases could have received an 
incorrect diagnosis in the beginning. We found evidence for this, with cases having 
more diagnoses for conditions like sleep apnoea and hypersomnia. Therefore, to 
explore this we performed a second analysis looking at vaccinated individuals only. In 
this analysis, we excluded cases/controls with an index date prior to vaccination. We 
found that nearly all the initially observed associations were no longer statistically 
significant and effect sizes were smaller (OR range=1.3-2.6) (Table 2 & 3 in Paper I). 
 
However, as early cases (those that had an MSLT-referral before vaccination) had 
been excluded from the second analysis, it was hypothesised that it was actually these 
cases that were responsible for the associations observed in the full data analysis. This 
is assuming that these early cases received more prescriptions/diagnoses before 
vaccination (and thus during vaccination period and before the index date) than those 
who were referred after vaccination. It can also be speculated that cases resulting after 
vaccination, would have had a shorter diagnostic timeframe (fewer misdiagnoses) 
given the increased awareness surrounding narcolepsy.  
 
To confirm if this and establish if there was a difference between these early cases 
and vaccine-associated cases, we performed a final analysis comparing cases referred 
before vaccination to those referred after. We only found large significant effects for 
prescriptions for nervous system disorders (OR=26.0 95% CI 4.0-170.2) and ADHD 
(OR=35.3 95% CI 3.4-369.9) during the vaccination period (See Table 4, in paper I) 
These findings supports the speculation that early cases were driving the associations 
found in the full data analysis and the significant effects were likely a result of 
confounding by indication and that disease history is not a risk factor for narcolepsy 
after A(H1N1)pdm09 vaccination. 
 
5.2 STUDY II 
 
 
In study II, the risk for condyloma after qHPV vaccination was estimated by 
including 264 498 girls, aged under 20 years, of whom 72 042 had received two doses 
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and 185 456 had received all three doses at the end of the study period. The majority 
of girls (83%) who were fully vaccinated had adhered to the recommended dosing 
schedule (0, 2, 6 months). The lowest rates of condyloma after two dose vaccination 
were observed in girls first initiation vaccination under the age of 17 years with 0-3 
months between dose one and two (IR=84 95% CI 66-108) per 100 000 person-years. 
Conversely, The highest rates of condyloma after two-dose vaccination were observed 
in girls first initiating vaccination after the age of 17 years when there were 8+ 
months between dose one and two (IR= 603 95% CI 271-1343) per 100 000 person-
years.  
 
Comparing two doses versus standard three-dose schedule, we found that for girls 
first vaccinated before the age of 17 the IRR of condyloma after receipt of two doses 
with 0-3 months between dose one and two was 1.96 (95% CI 1.43-2.68) and for 4-7 
months and 8+ months the IRR were 1.27 (95% CI 0.63-2.58) and 4.36 (95% CI 2.05-
9.28) respectively. For girls initiating vaccination after the age of 17, a similar pattern 
was observed, with a higher risk for condyloma after two doses with 0-3 months 
between dose one and two and for 8+ months. However, we found no statistically 
significant association comparing two doses with 4-7 months in between versus the 
standard three doses (Table 7). 
 
Table 7. IRR comparing two-dose versus three-dose vaccination by age at 
vaccination initiation and time between dose one and two, adjusted for attained age. 
Age at first 
vaccination 
Number 
of doses 
Time between dose 1 and 2 
(months) 
IRR, 95%CI P-
value 
≤16yr 3 doses Standard dosing schedule (0, 2, 6) Ref Ref 
 2 doses 0-3  1.96 (1.44; 2.68) <0.001 
    4-7 1.27 (0.63; 2.58) 0.506 
    8+  4.36 (2.05; 9.28) <0.001 
          
17-19yr 3 doses Standard dosing schedule (0, 2, 6) Ref Ref 
 2 doses 0-3  2.12 (1.62; 2.77) <0.001 
    4-7 0.81 (0.36; 1.84) 0.615 
    8+  3.16 (1.40; 7.14) 0.006 
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Comparing two-dose versus three-dose vaccination, where the time between doses 
was matched e.g. two doses with 0-3 months between doses versus three doses with 
0-3 months between dose one and two, results remained much the same as above for 
both girls initiating vaccination before 17 years and those after. For 4-7 months and 
8+ months, we found non-significant associations for girls initiating vaccination 
before 17 years with IRRs of 0.87 (95% CI 0.33-2.32) and 3.14 (95% CI 0.65-15.09) 
respectively. For girls initiating vaccination after 17 years, no association was found 
for 4-7 months between dose one and two (Table 3 in paper II). 
 
The results from this study support the recommendations from EMA and SAGE and 
findings from immunogenicity trials. Evidently, reducing the number of required 
doses in the HPV vaccination schedule would be beneficial for a number of reasons: 
a) cost-effectiveness b) better compliance, c) better logistics in the programme. This 
study indicates that two doses is sufficient to confer protection provided that the 
timing between doses is optimal.  
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6. METHODOLOGICAL CONSIDERATIONS 
 
6.1 SELECTION BIAS 
 
In mass vaccination campaigns, such as those for pandemic influenza, the vaccine on 
offer is usually first targeted at higher risk individuals such as the elderly, pregnant 
woman, and children. However, the vaccination is not mandatory and thus individuals 
have to choose to be vaccinated. These people could, therefore, represent a more 
select group that somehow differ from those that choose not to be vaccinated - this is 
selection bias. Selection bias was a large problem in study I, not only did we have a 
select group of people choosing to receive the A(H1N1)pdm09 vaccine, but there also 
a large proportion of cases that did not want to participate in the study. It was not 
possible to ascertain any reason for refusal to participate and thus means to control for 
this selection bias.  
 
Selection bias was also a problem in study II, as most of the girls were 
opportunistically vaccinated during the follow-up so the younger girls (13 to 17 years) 
were eligible for subsided vaccination, but the remainder had to pay the entire cost of 
the vaccine. Thus, girls choosing to be vaccinated during this time period may 
represent a more select group – those willing to be vaccinated despite the cost. What 
is not known is whether other aspects, like education level, could have played a role 
in whether a girl chose to be vaccinated. This was less of a problem in study II, 
however, as girls entered the study following administration of dose two, therefore the 
‘decision’ whether to receive the qHPV vaccination in the first place (dose one) has 
already occurred. In addition, individuals that choose to be vaccinated could be 
considered more health-conscious and adhere more to health-seeking behaviours than 
those that do not receive the vaccination. It has been shown previously that girls at 
greater risk of condyloma, over the age of 20, are more likely to seek out vaccination 
against HPV [88], it was possible, therefore, to limit the risk of self-selection bias by 
excluding women over the age of 20 years.  
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6.2 DIAGNOSTIC BIAS 
 
In study I, diagnostic bias was a potential problem, as narcolepsy typically takes 
several years to develop and be diagnosed and in this lag time, misdiagnoses can 
occur. However, with the increased awareness of narcolepsy after the vaccination 
campaign, the time between symptom onset and diagnosis was shortened. To reduce 
the effects of diagnostic bias, we used the MSLT referral date (index date) and not the 
date of diagnosis as a proxy for diagnosis date. In addition, to account for the time 
between vaccination and diagnosis, we investigated several different exposure 
windows that were specific to each individual in the study based on their 
A(H1N1)pdm09 vaccination date and index date. 
 
6.3 RECALL BIAS  
 
In study I, the data was originally all self-reported. This led to a host of problems with 
data integrity, as many responses were missing or incomplete. We controlled for this 
by augmenting the self-reported data with exposure data from the Swedish healthcare 
registers, however, this was not possible for the date for A(H1N1)pdm09vaccination 
and this, therefore, remained the original self-reported response. Although we 
controlled for self-reported vaccination dates as best we could (by assigning 15th for 
missing dates, November for missing month in 2009 and January for missing month 
in 2010) we could not rule out recall bias – with cases being more likely to remember 
when and if they received the A(H1N1)pdm09 vaccination. This may have resulted in 
a potential overestimation of exposure in cases. However, as this study took place 
shortly after the vaccination campaign, we believe that the effects of recall bias would 
be very low as individuals are more likely to recall something that happened recently. 
 
6.4 MISCLASSIFICATION OF EXPOSURE 
 
In study II, there is possible misclassification of vaccination exposure, due to 
underreporting of HPV vaccinations in SVEAVAC. The impact of which would be 
girls considered falsely unvaccinated and therefore not enter the study at the 
administration of dose two. We did not consider this a big problem in our study, 
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however, as we additionally used dispensation dates (registered in PDR) to 
complement data from SVEAVAC, thus minimising risk of misclassification in our 
study.  
 
6.5 ATTAINED AGE 
 
In study II, the age at which an individual is vaccinated (age of vaccination initiation) 
does not change over time. However, during follow-up of a study an individual gets 
older i.e. they attain age. Therefore, age at vaccination initiation and attained age are 
two different things. To correct for effect modification by age at vaccination 
initiation, we grouped the girls into two age-at-first-vaccination categories and 
adjusted for attained age.   
 
6.6 UNDERESTIMATION OF DISEASE EXPOSURE 
 
In study I, we were unable to look at individual disease codes as part of the broader 
ATC and ICD10 categories as the study size was too small. It is also possible that less 
bacterial and viral infections were reported, as generally speaking individuals will 
only seek medical care for acute infections, resulting in an underestimation of disease 
exposure.
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7. CONCLUSIONS 
 
 
In study I, we found that disease history was not a risk factor for narcolepsy after 
A(H1N1)pdm09 vaccination. We found that there was potential for misdiagnosis in 
early cases i.e. those that presented with symptoms and were referred for an MSLT 
test before they were vaccinated with Pandemrix. This could mean that narcolepsy 
cases are being missed until later years and potentially increasing the incidence of 
other mental and behavioural disorders such as ADHD and depression.  
 
In study II, we found that for women first vaccinated before the age of 20 years, a 
two-dose qHPV vaccination schedule, with 4-7 months between doses, may be as 
effective as the recommended three-dose schedule. 
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8.  FUTURE DIRECTIONS 
 
 
“The impact of vaccination on the health of the world’s people is hard to exaggerate. 
With the exception of safe water, no other modality, not even antibiotics, has had such 
a major effect on mortality reduction and population growth.” 
 
Susan Plotkin and Stanley Plotkin. First Edition of ‘Vaccine’ [89] 
 
While many public health successes can be attributed to vaccination, the future can 
present on-going challenges. There are, for example, still diseases for which there are 
no effective vaccines e.g. malaria and HIV, and locations around the world where 
there are limited resources or infrastructures for vaccinations if any exist at all. The 
success of vaccination depends on the continuance of effective medical research – 
with the development of highly effective vaccines (longer-lasting immune response), 
a minimal number of required doses (more cost-effective), hardy vaccines (will 
survive transport without cooling) and those that are simple to administer. In addition, 
focus to date has been placed on acute infectious diseases, but now with the 
development of an effective vaccine against cervical cancer, the focus could shift to 
prevention of chronic diseases such as TB, other cancers and Alzheimer’s disease. 
 
Establishing the impact of the influenza vaccines following introduction into the 
population relies on repeated VE studies. However, before-after studies are difficult to 
conduct for influenza as VE is modest in comparison to other vaccines e.g. 
pneumococcal conjugate vaccine. In addition, seasonal influenza epidemics display 
considerable heterogeneity compounded by existing immunity within the population 
(prior vaccination or past exposure) and antigenic drift [90]. Influenza VE varies year 
to year as well, depending on the virus strains circulating and the degree of antigenic 
match between the influenza strain contained in the vaccine and the circulating strains 
in the population [90, 91]. Although the goal is to develop an effective universal 
vaccine that reduces the burden of disease, it is important to evaluate the economic 
impact of an influenza vaccination programme and this is something that the WHO is 
currently developing [92].  
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The HPV vaccines have been on the market for over a decade and the protective 
properties of the vaccines have been shown, for example, in Australia, the HPV rates 
dropped from 23% to 1% in women aged 18-24 years over the last 10 years [93]. 
However, the duration of protection following vaccination, against HPV infection and 
HPV related diseases is not known, therefore, continued monitoring with longer 
follow-up time is necessary. The 9-valent vaccine, which has been shown to have an 
increased impact in comparison to the qHPV vaccine [94] has also recently been 
approved for use, so we will not have any information about the long-term effects of 
the vaccine for some time to come.  
 
It has been shown that males are protected against HPV-related cancers through herd 
effects when the vaccination coverage amongst girls is 80%, but also that including 
the boys into the HPV vaccination programmes could see a further reduction in the 
number of cancers in both sexes [95]. However, despite the obvious reductions in 
HPV related diseases and infections and the potential to include boys into the 
programme, girls are still at risk of cervical cancer and will require screening. Yet, we 
do not know the long-term difference in protection between the different vaccines and 
how this will affect their screening requirements nor how the screening requirement 
for these girls might differ from those who are not vaccinated. Therefore, future 
guidelines will need regular adaption to factor in differing screening requirements for 
these girls while achieving cost-effectiveness and maximum prevention of HPV-
related infections and cancer.  
 
Vaccine hesitancy also needs recognition as a changing global issue that threatens the 
success of vaccination programmes. The concept of vaccine hesitancy is complex and 
made up of many determinants that can vary depending on the setting. Different 
countries, for example, can have different magnitudes of vaccine hesitancy and the 
approach to dealing with the problem needs to be different. Countries must factor this 
in when developing a plan to measure and deal with vaccine hesitancy in their 
countries. 
 
Duration of protection from vaccines administered as a child is also an important 
consideration for the future, as with people living longer additional booster shots may 
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be necessary. It is also something that individuals have to seek out for themselves, 
which not only requires the knowledge regarding the importance of vaccinations as an 
adult but the time commitment and ability to do so. One possible consideration is to 
make a life-long vaccination programme that is sustainable and standardised across 
Europe – a programme that an individual follows from birth until death. This 
programme could provide the means to develop new vaccines, improved accessibility, 
and new platforms with better information for risk-groups, travellers etc. and also 
focus on migrants that are entering into Sweden from countries with endemic, 
vaccine-preventable diseases. This idea has already been presented by the Swedish 
Public Health Agency [96] and could be a major break-through in ensuring a high 
uptake of vaccines and duration of protection in the population. 
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